Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Merge symbols : EBS save search
Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning
Published: 2022-03-11 (Crawled : 12:00) - globenewswire.com
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: -5.51%
H: 0.0%
C: 0.0%
treatment solutions phase 1 potential merge phase 2 phase 3
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021
Published: 2022-02-24 (Crawled : 01:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -1.05%
H: 0.0%
C: 0.0%
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: -1.65%
H: 0.0%
C: 0.0%
financial results solutions report results merge
Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022
Published: 2022-02-07 (Crawled : 12:30) - biospace.com/
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: 2.19%
H: 2.97%
C: -0.15%
financial results conference results merge
Founder and Executive Chairman of Emergent BioSolutions Announces RetirementFuad El-Hibri to Retire After More Than 20 Years
Published: 2022-01-14 (Crawled : 12:30) - biospace.com/
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: 1.84%
H: 0.0%
C: 0.0%
ces air merge
Emergent BioSolutions is to Participate in Investor Conferences
Published: 2022-01-03 (Crawled : 13:30) - biospace.com/
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: 0.74%
H: 10.09%
C: 9.55%
conference merge
Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
Published: 2021-12-16 (Crawled : 13:30) - biospace.com/
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: 3.55%
H: 2.32%
C: 0.54%
phase 1 vaccine influenza merge phase 2 phase 3
SiTime Set to Join S&P MidCap 400; Emergent BioSolutions to Join S&P SmallCap 600
Published: 2021-11-22 (Crawled : 23:00) - prnewswire.com
SPGI | News | $413.28 0.01% 0.26% 2.8M
|
Commercial Services
|
| O: -1.72%
H: 0.0%
C: 0.0%
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: 5.89%
H: 3.86%
C: 0.9%
merge set
Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021
Published: 2021-10-18 (Crawled : 11:00) - globenewswire.com
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: -3.26%
H: 1.6%
C: 0.52%
financial results results merge conference
Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
Published: 2021-09-14 (Crawled : 12:15) - globenewswire.com
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: 0.03%
H: 0.87%
C: -0.28%
covid vaccine multi-year merge
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19
Published: 2021-08-25 (Crawled : 11:00) - globenewswire.com
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: 0.0%
H: 2.91%
C: 2.5%
covid treatment phase 3 trial merge
Emergent BioSolutions to Participate in Investor Conferences
Published: 2021-08-23 (Crawled : 00:00) - globenewswire.com
MS | News 0 d | $93.85 0.1% -0.02% 3.3M
|
Finance
|
| O: 0.52%
H: 0.73%
C: 0.39%
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: -1.69%
merge conference
Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
Published: 2021-07-29 (Crawled : 20:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.33%
H: 0.35%
C: -0.32%
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: 1.66%
H: 2.7%
C: -1.54%
covid vaccine merge covid-19
Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021
Published: 2021-07-15 (Crawled : 11:00) - globenewswire.com
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: -0.94%
H: 4.82%
C: 4.12%
financial results results merge conference
UPDATED DEADLINE MONDAY: ROSEN, SKILLED INVESTOR COUNSEL, Reminds Emergent BioSolutions Inc. Investors With Losses Over $100K of the Updated June 21 Deadline in Securities Class Action Due to the Recently Declared Federal Court Holiday - EBS
Published: 2021-06-19 (Crawled : 00:20) - prnewswire.com
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
| Email alert
Add to watchlist
merge
EMERGENT BIOSOLUTIONS 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Emergent BioSolutions Inc. - EBS
Published: 2021-06-17 (Crawled : 00:00) - prnewswire.com
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -1.18%
H: 0.56%
C: -0.79%
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: -0.51%
H: 1.33%
C: -3.58%
merge
COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization
Published: 2021-06-11 (Crawled : 21:00) - globenewswire.com
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
| Email alert
Add to watchlist
covid vaccine drug merge authorized emergency use authorization
Class Action Lawsuit Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.
Published: 2021-06-08 (Crawled : 19:00) - prnewswire.com
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.37%
H: 1.09%
C: 0.98%
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: 1.11%
H: 1.69%
C: 0.68%
merge
Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.
Published: 2021-06-02 (Crawled : 17:00) - prnewswire.com
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: -0.1%
H: 0.41%
C: 0.16%
merge
Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
Published: 2021-05-26 (Crawled : 11:00) - globenewswire.com
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: 0.44%
H: 1.34%
C: 1.04%
phase 2 positive vaccine merge chikungunya
DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Emergent BioSolutions Inc. Securities Fraud Class Action Lawsuit
Published: 2021-05-23 (Crawled : 16:20) - prnewswire.com
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
| Email alert
Add to watchlist
merge
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.